# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Mahalia Jackson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML035-SYN-TD
- Date: 1964-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Beatrice Fontenot, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

EBUS result and pulmonology consultation. **S**

## History of present illness

Ms. Jackson returns two weeks after her first visit. The CT of the chest two days after that visit showed enlarged hilar and mediastinal lymph nodes and small nodules along the airways in both upper lobes. EBUS-guided needle aspiration five days ago found non-necrotizing granulomas in three lymph node stations, with negative stains for mycobacteria and fungi; cultures are growing nothing so far. The interferon-gamma release assay and HIV test from the first visit were negative. She stopped the over-the-counter calcium and vitamin D tablets as advised. Her breathlessness and cough are unchanged, and she had one more spell of palpitations while singing at church. She has postponed her concerts for the next three weeks. Dr. Asante-Miller saw her this morning, and she had full lung function tests. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Tissue | Non-necrotizing granulomas at stations 4R, 7 and 11L; stains negative; cultures pending; lavage lymphocytes 32 percent, CD4 to CD8 ratio 5.2 |
| Infection excluded so far | Interferon-gamma release assay and HIV negative; acid-fast and fungal stains negative |
| Lung function | FVC 74 percent and DLCO 62 percent of predicted |
| Symptoms | Breathlessness and cough unchanged; one more spell of palpitations |
| Work | Concerts postponed for three weeks |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired; no fever, night sweats or weight loss |
| Respiratory | Positive | Breathless on one flight of stairs; dry cough |
| Cardiovascular | Positive | One spell of palpitations with light-headedness; no chest pain or fainting |
| Eyes | Negative | No redness, pain or blurred vision |
| Integumentary | Negative | No rash, nodules or plaques |
| Psychiatric | Positive | Anxious about singing again; PHQ-9 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/78 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.7 °C; oxygen saturation 95% on room air; weight 91.6 kg; BMI 31.7 kg/m². All vital signs are synthetic.

FVC percent predicted: 74% (low); FEV1 percent predicted: 76% (low); FEV1/FVC ratio: 80%; DLCO percent predicted: 62% (low); Calcium: 10.7 mg/dL (high); Creatinine: 1.04 mg/dL; eGFR (CKD-EPI 1959): 65 mL/min/1.73 m²; PHQ-9: 6. All results are synthetic.

## Change since baseline

- Calcium: 10.8 mg/dL (high) at baseline, 10.7 mg/dL (high) at this visit **S**
- Creatinine: 1.08 mg/dL (high) at baseline, 1.04 mg/dL at this visit **S**
- eGFR (CKD-EPI 1959): 62 mL/min/1.73 m² at baseline, 65 mL/min/1.73 m² at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 91.6 kg; blood pressure 126/78, pulse 82 and irregular with ectopic beats; oxygen saturation 95 percent |
| Respiratory | Clear to auscultation; no crackles |
| Cardiovascular | Occasional ectopic beats; no murmur; no ankle swelling |
| Skin | No erythema nodosum, plaques or scar infiltration |
| Lymph nodes | No palpable cervical, axillary or inguinal nodes |
| Psychiatric | Warm, direct, worried |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pulmonary sarcoidosis with lymph node involvement** (D86.2). The three ATS criteria are met: a compatible picture (bilateral hilar adenopathy with perilymphatic nodules, lymphopenia, high calcium with a high 1,25-dihydroxyvitamin D), non-necrotizing granulomas on EBUS-guided aspiration, and no sign of tuberculosis, fungal infection or lymphoma so far, with the final cultures to come. Lung function shows mild restriction with a reduced DLCO, and she is symptomatic, so the lungs alone would justify treatment. Sarcoidosis is more common, and more often severe, in Black women. Because the ECG and her palpitations suggest heart involvement, Dr. Asante-Miller advises completing the cardiac tests, including FDG-PET, before any prednisone, which would blunt the PET. **S**
   - Holter tomorrow; echocardiogram this week; cardiac MRI and FDG-PET with dietary preparation within two weeks.
   - Eye examination by ophthalmology.
   - Hepatitis B and C serology drawn today, before immunosuppression.
   - Treatment decision at the review in two weeks.
2. **Palpitations with first-degree atrioventricular block and ventricular ectopy** (R00.2). Suspected cardiac sarcoidosis, to be confirmed or excluded by the tests above; no fainting and no high-grade block. **S**
   - Call 911 for fainting, chest pain or a sustained racing heart.
   - No driving long distances alone until the Holter result is known.
3. **Hypercalcemia** (E83.52). Calcium 10.7 mg/dL two weeks after stopping the supplement, with creatinine 1.04 mg/dL: from granulomas making active vitamin D. Treatment of the sarcoidosis will correct it. **S**
   - No calcium or vitamin D tablets; ordinary dietary calcium; plenty of fluids; avoid sun overexposure.
4. **Breathlessness and cough with hilar adenopathy** (R06.09). Explained by the diagnosis confirmed today; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Tissue diagnosis | Once, when the diagnosis is uncertain from the clinical picture | Up to date | EBUS-guided needle aspiration rather than mediastinoscopy: non-necrotizing granulomas at three stations; no malignant cells |
| Laboratory | Exclusion of other granulomatous causes | At diagnosis | Ordered | Acid-fast and fungal stains negative; mycobacterial and fungal cultures pending, final in six to eight weeks; interferon-gamma release assay and HIV negative from the first visit |
| Imaging | Spirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO) | At diagnosis, three months after starting treatment, then every three to six months while treatment changes | Completed today | FVC 74 percent, FEV1 76 percent, FEV1/FVC 80 percent, DLCO 62 percent of predicted: mild restriction with reduced gas transfer |
| Laboratory | Serum calcium | At diagnosis, then at each treatment visit while it was raised or vitamin D is given | Completed today | 10.7 mg/dL off the supplement |
| Laboratory | Kidney function | At diagnosis, then with calcium checks | Completed today | Creatinine 1.04 mg/dL, eGFR 65 |
| Laboratory | 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D | At diagnosis, and before any vitamin D replacement | Up to date | From the first visit: 25-hydroxyvitamin D 22 ng/mL (low) and 1,25-dihydroxyvitamin D 84 pg/mL (high), so vitamin D is not to be given while calcium is high |
| Laboratory | Liver tests, alkaline phosphatase and blood count | At diagnosis | Up to date | From the first visit: alkaline phosphatase 128 U/L, ALT 28 U/L; lymphocytes 0.9; to be followed on treatment |
| Examination | Baseline ECG | At diagnosis for every patient | Up to date | First visit: first-degree atrioventricular block and frequent ventricular ectopy |
| Examination | Holter monitoring | When the ECG is abnormal or there are palpitations | Ordered | Tomorrow |
| Imaging | Echocardiogram | When cardiac involvement is suspected | Ordered | This week |
| Imaging | Cardiac MRI with late gadolinium enhancement | When cardiac involvement is suspected | Ordered | Within two weeks |
| Imaging | Cardiac FDG-PET | When cardiac involvement is suspected, before glucocorticoids | Ordered | Within two weeks, after a 72-hour high-fat, very-low-carbohydrate diet |
| Examination | Eye examination | At diagnosis for every patient, then yearly | Ordered | Ophthalmology appointment next week |
| Laboratory | Hepatitis B and C screening | Before immunosuppressive treatment | Ordered | Hepatitis B surface antigen, core antibody and surface antibody, and hepatitis C antibody drawn today |
| Laboratory | Serum angiotensin-converting enzyme | Not used for diagnosis | Not indicated | Not drawn: its sensitivity and specificity are too low to confirm or exclude sarcoidosis, and the diagnosis rests on tissue |
| Referral | Pulmonology (sarcoidosis) | At diagnosis | Completed today | Seen this morning; recommendations in the consultation note |
| Survey | Depression screen (PHQ-9) | At diagnosis and at each phase of treatment | Completed today | PHQ-9 6 |

## Goal progress

- Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation. In progress; target 1964-03-09. **S**
- Calcium in the normal range within three months. In progress; target 1964-05-11. **S**
- FVC and DLCO improved by at least 10 percent of predicted within six months. In progress; target 1964-08-24. **S**
- No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better. In progress; target 1964-08-24. **S**
- Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent. In progress; target 1964-08-24. **S**
- Back on stage with a schedule she can sustain, with her voice protected. In progress; target 1964-08-24. **S**

## Guideline basis

- Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020), American Thoracic Society
- Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021), European Respiratory Society
- Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014), Heart Rhythm Society
- Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024), American Heart Association
- Baughman RP, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc 2016;13(8):1244-1252 (PMID 27509154) (2016), Annals of the American Thoracic Society
- Mirsaeidi M, et al. Racial difference in sarcoidosis mortality in the United States. Chest 2015;147(2):438-449 (PMID 25188873) (2015), CHEST
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Holter, echocardiogram, eye examination, cardiac MRI and FDG-PET within two weeks; review in two weeks to decide treatment. Call 911 for fainting, chest pain or a sustained racing heart. **S**
- Next scheduled visit 1964-03-09: cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referral. **S**
